37 related articles for article (PubMed ID: 2822645)
1. Ring-fused 2-pyridones effective against multidrug-resistant Gram-positive pathogens and synergistic with standard-of-care antibiotics.
Nye TM; Tükenmez H; Singh P; Flores-Mireles AL; Obernuefemann CLP; Pinkner JS; Sarkar S; Bonde M; Lindgren AEG; Dodson KW; Johansson J; Almqvist F; Caparon MG; Hultgren SJ
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2210912119. PubMed ID: 36252016
[TBL] [Abstract][Full Text] [Related]
2. The antibiotic vancomycin induces complexation and aggregation of gastrointestinal and submaxillary mucins.
Dinu V; Lu Y; Weston N; Lithgo R; Coupe H; Channell G; Adams GG; Torcello Gómez A; Sabater C; Mackie A; Parmenter C; Fisk I; Phillips-Jones MK; Harding SE
Sci Rep; 2020 Jan; 10(1):960. PubMed ID: 31969624
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin Pore Formation and Stoichiometry Depend on Membrane Potential of Target Membrane.
Seydlová G; Sokol A; Lišková P; Konopásek I; Fišer R
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323037
[TBL] [Abstract][Full Text] [Related]
4. The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination.
Smith KP; Kirby JE
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784837
[TBL] [Abstract][Full Text] [Related]
5. A current perspective on daptomycin for the clinical microbiologist.
Humphries RM; Pollett S; Sakoulas G
Clin Microbiol Rev; 2013 Oct; 26(4):759-80. PubMed ID: 24092854
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
Cotroneo N; Harris R; Perlmutter N; Beveridge T; Silverman JA
Antimicrob Agents Chemother; 2008 Jun; 52(6):2223-5. PubMed ID: 18378708
[TBL] [Abstract][Full Text] [Related]
7. Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.
Snydman DR; Jacobus NV; McDermott LA; Lonks JR; Boyce JM
Antimicrob Agents Chemother; 2000 Dec; 44(12):3447-50. PubMed ID: 11083657
[TBL] [Abstract][Full Text] [Related]
8. Current perspectives on glycopeptide resistance.
Woodford N; Johnson AP; Morrison D; Speller DC
Clin Microbiol Rev; 1995 Oct; 8(4):585-615. PubMed ID: 8665471
[TBL] [Abstract][Full Text] [Related]
9. Influence of Ly146032 on chemotaxis, chemiluminescence of PMN and lymphocyte transformation in vitro.
Schubert S; Ullmann U
Infection; 1989; 17(6):374-7. PubMed ID: 2559038
[TBL] [Abstract][Full Text] [Related]
10. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.
Wood CA; Finkbeiner HC; Kohlhepp SJ; Kohnen PW; Gilbert DN
Antimicrob Agents Chemother; 1989 Aug; 33(8):1280-5. PubMed ID: 2552905
[TBL] [Abstract][Full Text] [Related]
11. Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats.
Beauchamp D; Pellerin M; Gourde P; Pettigrew M; Bergeron MG
Antimicrob Agents Chemother; 1990 Jan; 34(1):139-47. PubMed ID: 2158272
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.
Hanberger H; Nilsson LE; Maller R; Isaksson B
Antimicrob Agents Chemother; 1991 Sep; 35(9):1710-6. PubMed ID: 1659305
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.
Rybak MJ; Bailey EM; Lamp KC; Kaatz GW
Antimicrob Agents Chemother; 1992 May; 36(5):1109-14. PubMed ID: 1324637
[TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
Benson CA; Beaudette F; Trenholm G
J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
[TBL] [Abstract][Full Text] [Related]
15. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
[TBL] [Abstract][Full Text] [Related]
16. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
Pohlod DJ; Saravolatz LD; Somerville MM
J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
Coudron PE; Johnston JL; Archer GL
J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
[TBL] [Abstract][Full Text] [Related]
18. Mode of action and in-vitro activity of vancomycin.
Watanakunakorn C
J Antimicrob Chemother; 1984 Dec; 14 Suppl D():7-18. PubMed ID: 6440886
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin.
Wilhelm MP
Mayo Clin Proc; 1991 Nov; 66(11):1165-70. PubMed ID: 1943250
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
